PTC Therapeutics

The biotech space can be an investor's delight, fetching staggering returns, while at the same time taking them through the throes of despair if bets go wrong — all courtesy of make-or-break events. In September, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) has lost 0.44...

Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) soared more than 80 percent higher on Friday. The company confirmed that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the renewal of the company's therapy called Translarna (ataluren...

Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) spiked higher by more than 7 percent on Friday, but are still lower by nearly 35 percent year-to-date. The company reported results from a Phase 3 ACT DMD clinical trial of Translarna on Thursday. Debjit Chattopadhyay of Roth Capital maintained a...

U.S. stocks were little moved with the news-flow light, as would be expected prior to a long-weekend. In fact, Thursday's trading session proved to be the second lowest volume day of 2014. The S&P 500 closed above 1,900 and came within striking distance of matching its intraday all time...

You’ve heard of story stocks like Tesla that have logged 2013 gains of more than 300 percent but that’s nothing compared to our list of the biggest winners of the year. Sure, the year isn’t over yet but it’s unlikely that things will change much in the next week. In order to give credit where...